Loading…

Loading grant details…

Active HORIZON European Commission

Patient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT)

€6.68M EUR

Funder European Commission
Recipient Organization Aristotelio Panepistimio Thessalonikis
Country Greece
Start Date Nov 01, 2024
End Date Apr 30, 2028
Duration 1,276 days
Number of Grantees 54
Roles Participant; Associated Partner; Third Party; Coordinator
Data Source European Commission
Grant ID 101163781
Grant Description

BackgroundHealth systems face a time of unprecedented change, with spiraling costs, increasing cultural disparity in access to healthcare and research, and an infrastructure that is decades old.

Today, telehealth is a realistic alternative making care and research more accessible and personalised with less burden to better support the most vulnerable and under-served in our society.

The ability to test and monitor for illnesses using Patient Centric micro-Sampling (PCmS) is at the centre of this reform.Aim and main objectivesThis project is designed to build upon existing pilots and knowledge, then collaborate cross-sectorially to co-create and test the logistics, infrastructure and tools required to make PCmS a core healthcare tool and an acceptable alternative to venous blood-draw across Europe.

This project aligns with many IHI’s objectives focusing on cross-sectorial collaboration, emphasizing patient and end-user- centric co-design of outputs, harmonised regulatory and data generation approaches enhancing the potential of digital innovations in healthcare, while aiming to reduce the environmental footprint during the project and in final outputs to ensure that the expected long-term impact is a reachable reality that will deliver significant benefit to the community and address unmet public health needs at scale.To achieve our objectives, we bring together a broad group of required expertise, know-how and end-users (i.e., public and patients) to form a public-private-partnership specifically equipped to tackle this challenge.

This collaborative approach where the relevant stakeholders such as healthcare professionals, regulatory agencies and patients are involved and integrated to deliver solutions and innovation across healthcare systems and ensure the best chances for success and long-term positive impact from this project.Key deliverables include:1)An optimized, tested and validated ‘Gold Standard’ infrastructure and workflow for PCmS across Europe as a proven and reliable alternative to venipuncture2)Harmonised and clear regulatory and HTA pathways, standards and acceptability, measures and cost-benefit models across Europe3)Documented evidence to draw a citable ‘line in the sand’ for future research to support decisions to integrate PCmS into decentralised trials and care pathways4)Stakeholder engagement and patient involvement models and research on preferences and acceptability for PCmS5)Foundation for future: Enable access to the developed PCmS scientific findings, tools and assessment measures for rapid uptake and integration of PCmS approaches into decentralised clinical studies and healthcareExpected impact:-Patient-centric microsampling becomes an accepted alternative to the current standard of care venipuncture and the data gathered can be leveraged in healthcare planning.-Lowered patient burden and lowered barrier to access in situations where blood samples need to be collected, whether as part of diagnosis, care plan, health monitoring etc. -A solution to leverage high amounts of data gathered from increased testing can be explored already in this project so that it can pave the way for future research that can improve health outcomes.

All Grantees

Siemens Healthineers Ag; Rhinostics, Inc.; Medipace Limited; Pfizer Limited; Lilly Deutschland Gmbh; Institut Catala de la Salut; Abbvie Inc; Fundacio Privada Per A la Recerca I la Docencia Sant Joan de Deu; Glaxosmithkline Research & Development Limited; Patient Centric Sampling Interest Group Cic; Stichting Vu; Becton Dickinson France Sas; Aristotelio Panepistimio Thessalonikis; Fundacio Institut Universitari Pera la Recerca A L'Atencio Primaria de Salut Jordi Gol I Gurina; Novartis Pharma Ag; University of Dundee; Pharma Quality Europe Srl; Astrazeneca Ab; Jones Lang Lasalle Se; Stichting Sanquin Bloedvoorziening; University of Newcastle Upon Tyne; Thetabiomarkers Ike; F. Hoffmann-la Roche Ag; Tasso Inc; Glaxosmithkline Biologicals Sa; Hospital Sant Joan de Deu; Collaborate Healthcare- Kainotomes Ypiresies Ygeias Ike; Eli Lilly Kinsale Ltd; Yourbio Health, Inc.; Euraxi Pharma; Fundacion Para la Investigacion de Malaga En Biomedicina Y Salud; Institut Pasteur; Capitainer Ab; European Centre for Clinical Research Training; Univerzita Palackeho V Olomouci; Miebach Consulting Gmbh; Karolinska Institutet; Pfizer Inc; Iqvia Solutions Belgium; Trajan Scientific Europe Ltd; Bayer Aktiengesellschaft; Servicio Andaluz de la Salud; Region Stockholm; Institut de Recherches Servier; Bayer Spa; Institut de Recherches Internationales Servier; Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca; Technologie Servier; Eli Lilly and Company; Labcorp Early Development Laboratories Limited; Roche Diagnostics International Ag; Janssen Pharmaceutica Nv; International Doping Tests Management Ab Idtm; Pfizer R&D Uk Limited

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant